Brigatinib is a inhibitor used for ALK-positive metastatic NSCLC. It stops ALK signaling. You can get it in 30 mg, 90 mg, or 180 mg tablet forms, all with a film coating.
You start with 90 mg once a day for the first week, then switch to 180 mg every day. The tablets come in bottles with 30 pills each. It’s a big deal for lung cancer, especially since it goes after the ALK protein that’s common in some lung cancer cells.
By blocking this protein, brigatinib slows down the cancer cells from growing and spreading. They designed the dosing schedule to make the drug work well and reduce side effects. You start with a lower dose so your body can get used to it before you go to the higher maintenance dose.
The tablets are coated to keep the good stuff safe and make it easier for patients to swallow.
Reviews
There are no reviews yet.